MY
MYX.AU Mayne Pharma Group Ltd
- Market cap
- AUD 208M
- P/E
- 8.2x
- P/B
- 0.53x
- ROE
- 6.3%
- Dividend yield
- -
- Fundamental score
- 2.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is MYX.AU undervalued?
Graham numberMYX.AU trades 56.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mayne Pharma Group Ltd fundamental analysis
13 of 22 checks passedROE 0/2
Low return on equity (6.3%), below 10%.
ROA 1/1
Return on assets (2.7%) is above the industry median (-8.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (119.4%) is above the industry median (42.8%).
Revenue Growth 2/2
Revenue grew 27.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (11.0%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 1/1
PE (8.2x) is below the market median (15.0x).
PE vs Industry 1/1
PE (8.2x) is below the industry median (21.9x).
PBV 1/1
Price to book (0.5x) is below the industry median (2.0x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 4.4, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Mayne Pharma Group Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes speci…
Full company profileMayne Pharma Group Ltd financial statements
Mayne Pharma Group Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 573M | 530M | 525M | 457M | 401M | 157M | 184M | 388M | 408M | 384M |
| Gross Profit | 249M | 184M | 209M | 141M | 127M | 23.7M | 26.8M | 219M | 247M | 192M |
| Operating Income | 122M | 37.1M | 29.2M | -12.1M | 1.36M | -122M | -186M | -139M | -23.6M | -34.3M |
| EBITDA | 201M | -71.1M | -241M | -34.0M | -182M | -78.9M | -194M | -117M | 47.2M | 29.4M |
| Net Income | 88.6M | -134M | -279M | -92.8M | -208M | -281M | 117M | -174M | -93.8M | 24.5M |
| EPS | 1.21 | -1.83 | -3.79 | -1.21 | -2.65 | -3.58 | 1.41 | -2.19 | -1.19 | 0.23 |
| Balance Sheet | ||||||||||
| Total Assets | 1.91B | 1.83B | 1.64B | 1.83B | 1.46B | 1.29B | 1.25B | 1.14B | 1.01B | 909M |
| Total Liabilities | 602M | 595M | 622M | 783M | 692M | 731M | 613M | 689M | 644M | 519M |
| Shareholders' Equity | 1.30B | 1.23B | 1.01B | 1.04B | 768M | 565M | 634M | 454M | 370M | 391M |
| Cash & Short-term Investments | 69.2M | 94.1M | 89.0M | 138M | 98.0M | 96.7M | 220M | 149M | 100M | 82.2M |
| Total Debt | 340M | 374M | 369M | 398M | 347M | 414M | 47.5M | 38.8M | 41.3M | 43.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -15.2M | 121M | 107M | 99.8M | 47.3M | -7.21M | -42.7M | -15.3M | 17.5M | 15.6M |
| Capital Expenditure | 104M | 54.2M | 11.9M | 47.1M | 25.1M | 11.9M | 220M | 20.9M | 12.3M | 2.95M |
| Free Cash Flow | -120M | 67.3M | 94.7M | 52.7M | 22.2M | -28.5M | -262M | -36.2M | 5.19M | 12.7M |
| Ratios | ||||||||||
| ROE | 6.8% | -10.9% | -27.7% | -8.9% | -27.1% | -49.8% | 18.5% | -38.4% | -25.3% | 6.3% |
| ROA | 4.6% | -7.3% | -17.1% | -5.1% | -14.2% | -21.8% | 9.4% | -15.2% | -9.2% | 2.7% |
| Net Profit Margin | 15.5% | -25.3% | -53.2% | -20.3% | -52.0% | -179.0% | 63.9% | -44.9% | -23.0% | 6.4% |
| Debt to Equity | 0.26x | 0.31x | 0.37x | 0.38x | 0.45x | 0.73x | 0.07x | 0.09x | 0.11x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mayne Pharma Group Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jan 18, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 45.3M | 0.54 | 38.6% |
| 2022 | AUD 45.3M | 0.58 | - |
| 2021 | AUD 45.3M | 0.58 | - |
| 2020 | AUD 45.3M | 0.59 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | AUD 858M | 12 | 969.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Jan 18, 2023.
Who owns Mayne Pharma Group Ltd
- Insiders 22.61%
- Institutions 24.81%
- Public & others 52.58%
- Shares outstanding 81.9M
- Free float 44.1M
Top funds holding MYX.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| DFA International Small Cap Value Portfolio | 23.0M | 1.37% | - | Jan 2021 |
| Vanguard International Stock Index-Total Intl Stock Indx | 22.4M | 1.33% | - | Oct 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 10.5M | 0.63% | - | Dec 2020 |
| DFA Asia Pacific Small Company Series | 9.52M | 0.57% | - | Jan 2021 |
| iShares MSCI EAFE Small Cap ETF | 6.51M | 0.39% | - | Feb 2021 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 4.45M | 0.26% | - | Oct 2020 |
| DFA International Core Equity Portfolio | 3.94M | 0.23% | - | Jan 2021 |
| College Retirement Equities Fund-Stock Account | 3.62M | 0.22% | - | Dec 2020 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 2.33M | 0.14% | - | Nov 2020 |
| TIAA-CREF Funds-Quant International Small Cap Equity Fund | 2.30M | 0.14% | - | Jan 2021 |
Mayne Pharma Group Ltd company profile
- Company name
- Mayne Pharma Group Ltd
- Ticker
- MYX.AU
- ISIN
- AU000000MYX0
- Exchange
- Australian Securities Exchange
- Listed since
- Jun 29, 2007
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 363
- Fiscal year end
- June
- Address
- 1538 Main North Road, Salisbury South, SA, Australia, 5106
- Phone
- 61 8 8209 2666
- Website
- maynepharma.com
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Mayne Pharma Group Ltd management
10- Mr. Aaron GrayChief Executive Officer
- Mr. Griffin D. BuchananChief Financial Officer
- Dr. Thomas Duthy M.B.A., Ph.D.Manager of Investor Relations
- Ms. Kimberly Parker J.D.Executive VP & General Counsel
- Mr. Brant SchofieldExecutive Vice President of Corporate Development · born 1966
- Ms. Kate SurdezVP & Global Head of Human Resources
- Mr. Daniel MoorePresident of DistributeRx
- Dr. Frank Casty M.D.Executive VP, Global Head of R&D and Chief Medical Officer
- Mr. Tony RamyExecutive Vice President of Women's Health
- Mr. Brenton WalterFinancial Controller